KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Gains from Investment Securities: 2010-2024

Historic Gains from Investment Securities for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $53.3 million.

  • Supernus Pharmaceuticals' Gains from Investment Securities rose 194.16% to $7.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $15.2 million, marking a year-over-year increase of 21.75%. This contributed to the annual value of $53.3 million for FY2024, which is 45.49% up from last year.
  • Supernus Pharmaceuticals' Gains from Investment Securities amounted to $53.3 million in FY2024, which was up 45.49% from $36.6 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Gains from Investment Securities high stood at $53.3 million for FY2024, and its period low was $16.2 million during FY2022.
  • Moreover, its 3-year median value for Gains from Investment Securities was $36.6 million (2023), whereas its average is $35.4 million.
  • In the last 5 years, Supernus Pharmaceuticals' Gains from Investment Securities plummeted by 44.55% in 2021 and then soared by 125.94% in 2023.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Gains from Investment Securities stood at $45.4 million in 2020, then tumbled by 44.55% to $25.2 million in 2021, then slumped by 35.69% to $16.2 million in 2022, then spiked by 125.94% to $36.6 million in 2023, then soared by 45.49% to $53.3 million in 2024.